ArticleAnnals of neurology2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
Abstract read
In one paragraph
Article in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and prognostic value of blood neurofilament light chain in ischemic stroke: an individual patient data meta-analysis.Journal of neurology · 2026Pooled it
- Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.European journal of neurology · 2025Trial
- Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.Annals of neurology · 2026Article
- Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP.Translational psychiatry · 2026Article
- Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.BMC neurology · 2026Article
- Anti-CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?Annals of clinical and translational neurology · 2026Article
- Beyond Relapses: A Multimodal Biomarker Framework for Progression Independent of Relapse Activity and Smouldering Multiple Sclerosis.Brain sciences · 2026Review
- Article
- GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.Brain : a journal of neurology · 2026Article
- Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts.Translational stroke research · 2026Article
- Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Serum and CSF neurofilament light chain and glial fibrillary acidic protein levels in idiopathic intracranial hypertension.The journal of headache and pain · 2026Observational
- Towards primary prevention of multiple sclerosis.Nature reviews. Neurology · 2026Review
- Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Hereditary Transthyretin Amyloidosis Polyneuropathy.Journal of the peripheral nervous system : JPNS · 2026Article
- Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression.Communications medicine · 2026Article
- Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.Journal of neurology · 2026Article
- Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.Therapeutic advances in neurological disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors.
Pascal Benkert *Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-6525-8174
Aleksandra Maleska Maceski *Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Sabine SchaedelinMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Johanna OechteringMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-5359-7961
Amar ZadicMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Juan Francisco Vilchez GomezMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Lester Melie-GarciaMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Alessandro CagolMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-7703-0553
Riccardo GalbuseraMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-3092-8737
Suvitha SubramaniamMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Johannes LorscheiderMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Edoardo GalliMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Jannis MuellerMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0003-1394-8231
Bettina Fischer-BarnicolMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Lutz AchtnichtsDepartment of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
Oliver FindlingDepartment of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
Patrice H LaliveDepartment of Clinical Neurosciences, Division of Neurology, and Department of Medicine, Translational Biomarker Group, Geneva, Switzerland.
Claire BridelDepartment of Clinical Neurosciences, Division of Neurology, and Department of Medicine, Translational Biomarker Group, Geneva, Switzerland.
Marjolaine UginetDepartment of Clinical Neurosciences, Division of Neurology, and Department of Medicine, Translational Biomarker Group, Geneva, Switzerland.
Stefanie MüllerDepartment of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Caroline PotService of Neurology and Laboratories of Neuroimmunology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Amandine MathiasService of Neurology and Laboratories of Neuroimmunology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Renaud Du PasquierService of Neurology and Laboratories of Neuroimmunology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Anke SalmenDepartment of Neurology, St Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Robert HoepnerDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Andrew ChanDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Giulio DisantoMultiple Sclerosis Center, Neurocenter of Southern Switzerland, EOC, Lugano, Switzerland.
Chiara ZeccaMultiple Sclerosis Center, Neurocenter of Southern Switzerland, EOC, Lugano, Switzerland.
Marcus D'SouzaMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Lars G HemkensMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Özgür YaldizliMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Tobias DerfussMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Patrick RothDepartment of Neurology and Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Claudio GobbiMultiple Sclerosis Center, Neurocenter of Southern Switzerland, EOC, Lugano, Switzerland.
David BrassatNovartis Pharma AG, Basel, Switzerland.
Björn TackenbergDepartment of Neurology, Philipps-University, Marburg, Germany.
Rosetta PedottiF. Hoffmann-La Roche, Basel, Switzerland.
Catarina RaposoF. Hoffmann-La Roche, Basel, Switzerland.
Jorge OksenbergDepartment of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Klaus BergerInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Marco HermesdorfInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.ORCID https://orcid.org/0000-0003-3541-7212
Fredrik PiehlDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
David ConenPopulation Health Research Institute, McMaster University, Hamilton, Canada.
Andreas BuserRegional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
Ludwig KapposMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Michael KhalilDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0002-5350-3328
Cristina GranzieraMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Ahmed AbdelhakDepartment of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-9731-4169
David LeppertMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-6172-801X
Eline A J Willemse *Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Jens KuhleMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-6963-8892
Swiss MS Cohort study (SMSC)
Funding
International Progressive MS Alliance PA-2302-40851Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 320030_212534 / 1
Abstract
objectiveTo investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy (BCDT) and their capacity to prognosticate future progression independent of relapse activity (PIRA) events.
methodsA total of 362 pwMS (1,480 samples) starting BCDT in the Swiss Multiple Sclerosis (MS) Cohort were included. sGFAP levels in 2,861 control persons (4,943 samples) provided normative data to calculate adjusted Z scores.
resultsElevated sGFAP levels (Z score >1) at 1 year were associated with a higher hazard for PIRA (hazard ratio [HR]: 1.80 [95% CI: 1.17-2.78]; p = 0.0079) than elevated sNfL levels (HR, 1.45 [0.95-2.24], p = 0.0886) in a combined model. Independent of PIRA events, sGFAP levels longitudinally increased by 0.49 Z score units per 10 years follow-up (estimate, 0.49 [0.29, 0.69], p < 0.0001). In patients experiencing PIRA, sGFAP Z scores were 0.52 Z score units higher versus stable patients (0.52 [0.22, 0.83], p = 0.0009). Different sNfL Z score trajectories were found in pwMS with versus without PIRA (interaction p = 0.0028), with an average decrease of 0.92 Z score units per 10 years observed without PIRA (-0.92 [-1.23, -0.60], p < 0.0001), whereas levels in patients with PIRA remained high.
interpretationElevated sGFAP and lack of drop in sNfL after BCDT start are associated with increased risk of future PIRA. These findings provide a rationale for combined monitoring of sNfL and sGFAP in pwMS starting BCDT to predict the risk of PIRA, and to use sGFAP as an outcome in clinical trials aiming to impact on MS progressive disease biology. ANN NEUROL 2024.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.